Literature DB >> 34811741

Health-related quality of life and days alive without life support or out of hospital: Protocol.

Anders Granholm1,2, Olav Lilleholt Schjørring2,3,4, Aksel Karl Georg Jensen5, Benjamin Skov Kaas-Hansen5,6, Marie Warrer Munch1,2, Thomas Lass Klitgaard2,3,4, Elena Crescioli2,3,4, Maj-Brit Nørregaard Kjaer1,2, Thomas Strøm7,8, Anders Perner1,2, Bodil Steen Rasmussen2,3,4, Morten Hylander Møller1,2.   

Abstract

BACKGROUND: Mortality is often the primary outcome in randomised clinical trials (RCTs) conducted in critically ill patients. Due to increased awareness on survivors after critical illness and outcomes other than mortality, health-related quality of life (HRQoL) and days alive without life support (DAWOLS) or days alive and out of hospital (DAAOOH) are increasingly being used. DAWOLS and DAAOOH convey more information than mortality, are easier to collect than HRQoL, and are usually assessed at earlier time points, which may be preferable in some situations. However, the associations between DAWOLS-DAAOOH and HRQoL are uncertain.
METHODS: We will assess associations between DAWOLS-DAAOOH at day 28 and 90 (independent variables/predictors) and HRQoL assessed using the EuroQol EQ-5D-5L questionnaire (EQ-VAS and EQ-5D-5L index values) at 6 or 12 months (dependent variables) in two RCTs: the COVID STEROID 2 RCT conducted in adult patients with COVID-19 and severe hypoxaemia and the Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU) RCT conducted in adult intensive care patients with acute hypoxaemic respiratory failure. We will describe associations using best-fitting fractional polynomial transformations separately in each dataset, with the resulting models presented and assessed in both datasets graphically and using measures of fit and prediction adequacy (i.e., internal performance and external validation). We will use multiple imputation if missingness exceeds 5%. DISCUSSION: The outlined study will provide important knowledge on the associations between DAWOLS-DAAOOH and HRQoL in adult critically ill patients, which may help researchers and clinical trialists prioritise and select outcomes in future RCTs conducted in this population.
© 2021 The Acta Anaesthesiologica Scandinavica Foundation.

Entities:  

Keywords:  critical care; critical illness; days alive and out of hospital; days alive without life support; health-related quality of life; outcome selection; randomised clinical trials

Mesh:

Year:  2021        PMID: 34811741     DOI: 10.1111/aas.14001

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  2 in total

1.  Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial.

Authors:  Anders Granholm; Marie Warrer Munch; Sheila Nainan Myatra; Bharath Kumar Tirupakuzhi Vijayaraghavan; Maria Cronhjort; Rebecka Rubenson Wahlin; Stephan M Jakob; Luca Cioccari; Maj-Brit Nørregaard Kjær; Gitte Kingo Vesterlund; Tine Sylvest Meyhoff; Marie Helleberg; Morten Hylander Møller; Thomas Benfield; Balasubramanian Venkatesh; Naomi E Hammond; Sharon Micallef; Abhinav Bassi; Oommen John; Vivekanand Jha; Klaus Tjelle Kristiansen; Charlotte Suppli Ulrik; Vibeke Lind Jørgensen; Margit Smitt; Morten H Bestle; Anne Sofie Andreasen; Lone Musaeus Poulsen; Bodil Steen Rasmussen; Anne Craveiro Brøchner; Thomas Strøm; Anders Møller; Mohd Saif Khan; Ajay Padmanaban; Jigeeshu Vasishtha Divatia; Sanjith Saseedharan; Kapil Borawake; Farhad Kapadia; Subhal Dixit; Rajesh Chawla; Urvi Shukla; Pravin Amin; Michelle S Chew; Christian Aage Wamberg; Christian Gluud; Theis Lange; Anders Perner
Journal:  Intensive Care Med       Date:  2021-11-10       Impact factor: 17.440

Review 2.  Randomised clinical trials in critical care: past, present and future.

Authors:  Anders Granholm; Waleed Alhazzani; Lennie P G Derde; Derek C Angus; Fernando G Zampieri; Naomi E Hammond; Rob Mac Sweeney; Sheila N Myatra; Elie Azoulay; Kathryn Rowan; Paul J Young; Anders Perner; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2021-12-02       Impact factor: 41.787

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.